Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Source: CNBC
Original reporting
CNBC: read the full reportRelated stories
CNBC
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
CNBC
Anthropic CEO Dario Amodei charts a new direction for tech philanthropy
Anthropic CEO Dario Amodei has pledged a portion of his company shares to charity with unusual conditions, according to an SEC filing.
BBC Business
Poundland's future hangs in the balance as chain edges towards collapse
Poundland's bosses is filing a notice of intention to appoint administrators to the business.
CNBC
U.S. worker job engagement hits lowest level since 2011, new Gallup poll finds
Gallup finds U.S. worker engagement on the job sinking to a level not seen since 2011, with remote and hybrid employees and AI primary factors.
CNBC3 outlets
President of the European Central Bank Christine Lagarde to step down in February
Departure of Lagarde, seen as candidate to take over World Economic Forum, comes as eurozone struggles with weak growth and inflation Christine Lagarde, the eurozone’s top central banker, is stepping down nine months early, ending months of speculation about her future. The European Central Bank (ECB) announced on Thursday morning that Lagarde would step down as its president on 7 February 2027; her term was scheduled to run until the end of October next year. Continue reading...
CNBC
Putin praises Elon Musk as a ‘genius’ as Russia develops Starlink alternative
Russia is trying to develop is own version of the satellite constellation Starlink: Rassvet.